Cardiometabolic & kidneySecondary analysis
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease
- Post hoc analysis of a randomised controlled trial
- double-blind
- parallel-design
- 640 centres
Authors' conclusion
In this post hoc analysis, the dual GLP-1 and GIP agonist tirzepatide, compared with the GLP-1 agonist dulaglutide, was associated with a lower incidence of a broad 6-component composite cardiovascular and kidney end point in patients with diabetes and established cardiovascular disease.
Study context
- Population
- Patients with T2DM and established CVD
- Participants
- 13,165 patients
- Comparison
- Tirzepatide vs dulaglutide
- Tirzepatiden = 6,586
- Dulaglutiden = 6,579reference
- Primary endpoint
- Time to first 6-component cardiorenal composite:
- All-cause mortality
- Myocardial infarction (MI)
- Stroke
- Coronary revascularization
- HF hospitalization
- Adverse kidney outcomes composite
Primary result
As reported in the abstract
median treatment duration 46.9 months
Hazard ratio
0.84
95% CI 0.79–0.90
P < 0.001
Events by treatment group
Tirzepatide vs Dulaglutide
HR 0.84 (95% CI 0.79–0.90); P < 0.001
Further findings
Sensitivity analysis: 5-component end point (without kidney composite outcomes)
- HR (sensitivity analysis, 5-component end point)
- 0.86; 95% CI, 0.80-0.93
Sensitivity analysis: 4-component composite (without kidney or HF end points)
- HR (sensitivity analysis, 4-component composite)
- 0.86; 95% CI, 0.80-0.93
Safety
Gastrointestinal adverse events
Gastrointestinal adverse events
- Other adverse events similar
Original publication
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease. JAMA Cardiol. Published 1 June 2026. doi:10.1001/jamacardio.2026.0767
Summarised from the published abstract; every number is checked against it